Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
暂无分享,去创建一个
D. Hommes | W. Sandborn | W. Reinisch | J. Colombel | P. Pollack | J. Colombel | A. Robinson | K. Lomax | S. Schreiber | S. Schreiber | B. Huang